EUVIMEDEUVIMED entdecken
Fallbericht

The Efficacy of Sacubitril/Valsartan in the Treatment of Peripartum Cardiomyopathy: A Retrospective Analysis of Four Cases

Seçkin Dereli, Osman Eren Kır, Fatma Demirci

Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology · 14.08.2026 · 519

DOI: 10.5543/tkda.2025.33506 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology, online erschienen am 14.08.2026. Verfasst von Seçkin Dereli und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Ordu University Faculty of Medicine, Ordu, Türkiye. Hauptthemen laut MEDLINE: Peripartum Cardiomyopathy, Aminobutyrates, Tetrazoles, Angiotensin Receptor Antagonists.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peripartum cardiomyopathy (PPCM) is a rare form of cardiomyopathy that develops in the last months of pregnancy or during the postpartum period and is characterized by a decrease in left ventricular ejection fraction below 45%. The diagnosis and management of PPCM can be difficult because the symptoms of the disease may be confused with normal pregnancy symptoms. This requires physicians to maintain a high level of clinical suspicion. PPCM can be fatal if not correctly diagnosed and treated. In this case series, we describe the clinical course of four PPCM patients treated with sacubitril/valsartan (S/V) in addition to standard therapy. In these patients, S/V therapy was associated with improvements in left ventricular function. By the end of the first month, all patients demonstrated recovery of ejection fraction above 50% and were classified as New York Heart Association (NYHA) class I. These preliminary observations suggest that S/V may represent a potential treatment option for PPCM, although confirmation in larger studies is required. Although data on the use of S/V in PPCM remain limited, our case series provides preliminary insights that warrant further investigation. The management of PPCM requires a multidisciplinary approach, emphasizing the importance of timely intervention. Our observations indicate that S/V could be considered a possible therapeutic option, but confirmation in larger cohorts is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peripartum CardiomyopathyAminobutyratesTetrazolesAngiotensin Receptor AntagonistsPregnancy Complications, CardiovascularHumansFemaleDrug CombinationsBiphenyl CompoundsValsartanPregnancyAdultRetrospective StudiesTreatment Outcome

Substanzen

Drug CombinationsBiphenyl CompoundsAminobutyratesValsartansacubitril and valsartan sodium hydrate drug combinationTetrazolesAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Cardiology, Ordu University Faculty of Medicine, Ordu, Türkiye.

Zitieren

APA

Dereli, S., Kır, O. E., & Demirci, F. (2026). The Efficacy of Sacubitril/Valsartan in the Treatment of Peripartum Cardiomyopathy: A Retrospective Analysis of Four Cases. Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology, 519. https://doi.org/10.5543/tkda.2025.33506

Vancouver

Dereli S, Kır OE, Demirci F. The Efficacy of Sacubitril/Valsartan in the Treatment of Peripartum Cardiomyopathy: A Retrospective Analysis of Four Cases. Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology. 2026:519. doi:10.5543/tkda.2025.33506

BibTeX
@article{Dereli2026,
  author = {Dereli, Seçkin and Kır, Osman Eren and Demirci, Fatma},
  title = {The Efficacy of Sacubitril/Valsartan in the Treatment of Peripartum Cardiomyopathy: A Retrospective Analysis of Four Cases},
  journal = {Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology},
  year = {2026},
  pages = {519},
  doi = {10.5543/tkda.2025.33506}
}
Kostenlos starten →